Trial record 10 of 56 for:    cardiogenic shock

The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01993745
First received: October 29, 2013
Last updated: November 20, 2013
Last verified: November 2013
  Purpose

The study is to show the prognostic factor of HRV parameter and cardiac fibrosis markers in critical illness patients


Condition
Cardiogenic Shock,
With ECMO or IABP Support,
With APACH II Score >25)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • Heart Rate Variability and serum cardiac fibrosis markers in critical illness patients [ Time Frame: 2-4weeks ] [ Designated as safety issue: No ]
    1. Outcome measurement:

      The measure is a composite outcome measure consisting of multiple measures (results to be reported as a single value for each Arm/Group), no changes are required

    2. List the primary condition or disease being studied Shock needing ECMO support


Enrollment: 106
Study Start Date: May 2008
Study Completion Date: December 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
Study group
ECMO Patients survived
Control
ECMO Patient died

Detailed Description:

The analysis of Heart Rate Variability with 24hrs Holter ECG and serum cardiac fibrosis markers in critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score >25)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

adult age>18 years old

Criteria

Inclusion Criteria:

  • critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score >25)

Exclusion Criteria:

  • pacemaker rhythm, not sign the permit
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01993745

Locations
Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01993745     History of Changes
Other Study ID Numbers: 200804046R
Study First Received: October 29, 2013
Last Updated: November 20, 2013
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
ECMO
APACH II score

Additional relevant MeSH terms:
Shock
Shock, Cardiogenic
Critical Illness
Fibrosis
Disease Attributes
Pathologic Processes
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on April 15, 2014